Bionano Laboratories今日宣布，已就全基因组结构变异检测项目，收到MolDx提出的地方覆盖决定（LCD）拟议文本。这一决定聚焦于血液系统肿瘤的临床检测场景。
据悉，该拟议LCD将有望为相关检测技术建立起更明确的报销路径与临床适用性范畴。此举或对肿瘤精准诊断领域产生深远影响。
MolDx作为一个备受认可的分子诊断审查项目，其裁定往往被视为支付方政策的重要风向标。Bionano Laboratories此番推进，或意味着其技术平台正加速走向主流临床应用。检测范围的界定，无疑将成为业界持续关注的焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.